CAMBRIDGE, Mass., Sep 28, 2009 (GlobeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the closing of its underwritten public offering of 4,600,000 shares of its common stock, which includes the full exercise of the underwriter's over-allotment option of 600,000 shares. After underwriting discounts and commissions and estimated offering expenses, Momenta received net proceeds of approximately $46.7 million. Leerink Swann LLC acted as sole book-running manager for the offering. The shares were sold pursuant to the Company's existing shelf registration statement, base prospectus, and prospectus supplement as filed with the Securities and Exchange Commission.
This announcement shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Momenta Pharmaceuticals, Inc., nor shall there be any sale of securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Momenta
Momenta Pharmaceuticals is a biotechnology company, headquartered in Cambridge, MA, specializing in the detailed structural analysis of complex mixture drugs. Momenta is applying its technology to the development of generic versions of complex drug products, as well as to the discovery and development of novel drugs.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Momenta Pharmaceuticals
CONTACT: Momenta Pharmaceuticals, Inc. Beverly Holley 617-395-5189 bholley@momentapharma.com
(C) Copyright 2009 GlobeNewswire, Inc. All rights reserved.
News Provided by COMTEX
